NOMAN Races

Share this page:

Jul 20 - Aug 2 2019

The BARCELONA - IBIZA and IBIZA - BARCELONA races are NOMAN exclusive premier ocean rowing events. Teams of amateur rowers are pitted against each other across 200 miles in journey that is expected to last 3 days. Rowing across an ocean or sea is like no other sport. Ocean rowing is as much about the crew's’ ability to cope mentally, as it is about technique and physical strength.

In 2013 the Barcelona-Ibiza: Row to End HPV was NOMAN’s inaugural event and an outstanding success, raising over $1 million and attaining press on an national and international scale. In 2015, the capacity of the event was doubled as a second race from Ibiza to Barcelona was introduced. The capacity or the race was once again doubled in 2017 as 4 crews of rowers faced some of the toughest conditions in the five-year history of NOMAN, combating the blistering sun, fierce winds, fatigue and sea sickness.

NEXT RACES
BARCELONA - IBIZA: 20th – 28th July, 2019
IBIZA - BARCELONA: 25th July – 2nd  August, 2019

 

Donate Now View Event Website Take part in this Event

16-23 Jun 2018

In 2018, Team NOMAN RAAM will be be going aster the 8-person record currently set at [speed: 24.19 mph] [time: 5:03:45] by Team Allied Forces in 2013.

For 35 years RAAM has been challenging ultracyclists from around the globe to push their physical and mental limits to the farthest reaches. Starting in Oceanside, under one of the longest piers in California, RAAM spans 3000 miles, climbs 175,000 feet, crosses 12 states and finishes in Annapolis, Maryland, the east coast sailing mecca.

Visit the Cycling Microsite to register your interest or to find out more about other cycling challenges.

Past Events:

Cosaveli's Trois Etapes Giro (Italy): 4-7 June 2015 (winners)
Cosaveli's Trois Etapes Tour (France): 6-9 August 2015 (winners)
Cosaveli's Trois Etapes Giro (Italy): 6-9 June 2014 (2nd place)

 

Donate Now View Event Website Take part in this Event
Donate now, and together we can eliminate 100% of all HPV related cancers.